Dr. Amit Lahoti, MD

Dr. Lahoti practices at The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System.

Dr. Lahoti's NPI, 1649219148, was assigned on June 6, 2006. Dr. Lahoti graduated from Joe R. & Teresa Lozano Long School of Medicine in 1998. Dr. Lahoti's Texas license number on file is L2397.

Dr. Lahoti's primary practice is The University of Texas MD Anderson Cancer Center, at 1515 Holcombe Blvd, Houston, TX 77030.

Dr. Lahoti's primary practice is The University of Texas MD Anderson Cancer Center in Houston, Texas, part of The University of Texas System. The medical group on file is Physicians Referral Service.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Lahoti practices. Vendor and product names are available with a free account.

Nephrology is Dr. Lahoti's primary specialty in the NPI Registry, under taxonomy code 207RN0300X. Dr. Lahoti is board certified in nephrology by the American Board of Internal Medicine. Dmand AI has Dr. Lahoti's licenses on file in 10 states: Texas, Florida, Tennessee, Mississippi, Washington, Alabama, Arizona, Georgia, Louisiana and Oklahoma.

Dmand AI lists acute kidney failure, chronic kidney disease and fluid and electrolyte imbalances among the conditions Dr. Lahoti treats.

CMS data shows 735 Medicare services from Dr. Lahoti across 6 procedure codes in 2024, for 303 Medicare patients. Medicare paid $65,446 for them.

CMS counts 303 Medicare patients who saw Dr. Lahoti in 2024. The largest group is 65 to 74, with 155 patients. 75% of them have chronic kidney disease, and 75% have high blood pressure. 8% are also on Medicaid. Their average risk score is 4.09, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Lahoti's median patient age at 69, with 46% women.

In 2024, Dr. Lahoti wrote 83 Medicare Part D claims for 22 patients. 88% of them were for generic drugs. CMS names the drug for 11 of them, across 1 drug with 11 or more claims each, at $51 in total drug cost. In 2020, CMS named 26 claims across 2 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 84 out of 100 for Dr. Lahoti for performance year 2024, reported as part of a group. Dr. Lahoti accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Lahoti as offering telehealth.

Dmand AI links 14 papers to Dr. Lahoti, published from 2009 to 2017. 2011 was the busiest year, with 2. The most frequent topics are Acute Kidney Injury, Creatinine and Kidney Diseases. Dr. Lahoti has published most often in Cancer. Dr. Lahoti's most frequent co-authors are Abdulla K. Salahudeen, MD, Amit Lahoti, MD and Hagop M. Kantarjian, MD.

CMS Open Payments shows 42 general payments to Dr. Lahoti from 17 drug and device companies from 2016 to 2024. Speaker and faculty fees make up the largest share, 82% of the total. Pfizer Inc. paid the most, $7,200.

Dmand AI lists 4 awards for Dr. Lahoti, most recently President's Recognition for Faculty Excellence in Education and Mentorship Advancement in 2017.

Dr. Lahoti graduated from Joe R. & Teresa Lozano Long School of Medicine in 1998. Dr. Lahoti is a member of ACP, ASN and NKF.

Dr. Lahoti is in network with 7 carriers, including Aetna, Excellus BlueCross BlueShield and Blue Cross Blue Shield of Michigan. HMO plans come from the most carriers, 4. Check the plan with the practice before a visit.